[Skip to Content]
[Skip to Content Landing]
Viewpoint
October 2018

Moving Beyond Symptom Remission to Optimize Long-term Treatment of Attention-Deficit/Hyperactivity Disorder

Author Affiliations
  • 1Department of Psychiatry, Duke University School of Medicine, Durham, North Carolina
JAMA Pediatr. 2018;172(10):901-902. doi:10.1001/jamapediatrics.2018.1642

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric conditions; it affects millions of youth in the United States. The disorder is a significant public health challenge because it independently increases risk for a wide range of adverse social and health outcomes, including substance use and other psychiatric conditions, obesity, educational underattainment, incarceration, and even premature mortality.1 The cost of illness for ADHD has been estimated to be in the tens of billions of dollars annually in the United States alone.2

×